Page last updated: 2024-12-08
ly 97119
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
LY 97119: clofilium analog; blocks heart potassium channels; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 194450 |
CHEMBL ID | 3093959 |
SCHEMBL ID | 11131309 |
MeSH ID | M0158524 |
Synonyms (9)
Synonym |
---|
ly 97119 |
chembl3093959 , |
bdbm50095760 |
72456-59-8 |
benzenebutanamine, 4-chloro-n-ethyl-n-heptyl- |
n-[4-(4-chlorophenyl)butyl]-n-ethylheptan-1-amine |
SCHEMBL11131309 |
DTXSID70993258 |
AKOS040748828 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (1)
Inhibition Measurements
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | IC50 (µMol) | 0.0237 | 0.0009 | 1.9014 | 10.0000 | AID1058738; AID1058739 |
Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | Ki | 0.0196 | 0.0021 | 1.8407 | 10.0000 | AID1058739; AID1234160 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Activation Measurements
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) | Kd | 0.0160 | 0.0160 | 0.0160 | 0.0160 | AID1234163 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Biological Processes (22)
Molecular Functions (12)
Ceullar Components (5)
Process | via Protein(s) | Taxonomy |
---|---|---|
plasma membrane | Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) |
cell surface | Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) |
perinuclear region of cytoplasm | Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) |
voltage-gated potassium channel complex | Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) |
inward rectifier potassium channel complex | Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) |
plasma membrane | Potassium voltage-gated channel subfamily H member 2 | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Bioassays (8)
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID1058739 | Displacement of [3H]astemizole from human ERG channel expressed in HEK293 cell membrane after 1 hr by scintillation counting analysis | 2013 | Journal of medicinal chemistry, Dec-12, Volume: 56, Issue:23 | Removal of human ether-à-go-go related gene (hERG) K+ channel affinity through rigidity: a case of clofilium analogues. |
AID1234161 | Binding affinity to human Kv11.1 expressed in HEK293 cell membranes assessed as association rate constant by [3H]dofetilide competition association assay | 2015 | Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15 | Structure-Affinity Relationships (SARs) and Structure-Kinetics Relationships (SKRs) of Kv11.1 Blockers. |
AID1234164 | Binding affinity to human Kv11.1 expressed in HEK293 cell membranes assessed as binding residence time by [3H]dofetilide competition association assay | 2015 | Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15 | Structure-Affinity Relationships (SARs) and Structure-Kinetics Relationships (SKRs) of Kv11.1 Blockers. |
AID1058738 | Inhibition of human ERG channel expressed in HEK293 cells after 15 mins by whole-cell patch clamp technique | 2013 | Journal of medicinal chemistry, Dec-12, Volume: 56, Issue:23 | Removal of human ether-à-go-go related gene (hERG) K+ channel affinity through rigidity: a case of clofilium analogues. |
AID1234163 | Binding affinity to human Kv11.1 expressed in HEK293 cell membranes assessed as binding affinity constant by [3H]dofetilide competition association assay | 2015 | Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15 | Structure-Affinity Relationships (SARs) and Structure-Kinetics Relationships (SKRs) of Kv11.1 Blockers. |
AID1234160 | Displacement of [3H]dofetilide from human Kv11.1 expressed in HEK293 cell membranes by competitive radioligand displacement assay | 2015 | Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15 | Structure-Affinity Relationships (SARs) and Structure-Kinetics Relationships (SKRs) of Kv11.1 Blockers. |
AID1234162 | Binding affinity to human Kv11.1 expressed in HEK293 cell membranes assessed as dissociation rate constant by [3H]dofetilide competition association assay | 2015 | Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15 | Structure-Affinity Relationships (SARs) and Structure-Kinetics Relationships (SKRs) of Kv11.1 Blockers. |
AID1058736 | Ratio of Ki for human ERG channel expressed in HEK293 cell membrane after 1 hr by scintillation counting analysis to IC50 for human ERG channel expressed in HEK293 cells after 15 mins by whole-cell patch clamp technique | 2013 | Journal of medicinal chemistry, Dec-12, Volume: 56, Issue:23 | Removal of human ether-à-go-go related gene (hERG) K+ channel affinity through rigidity: a case of clofilium analogues. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (5)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 1 (20.00) | 18.7374 |
1990's | 2 (40.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (40.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.72
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.72) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |